Marinus Pharma (MRNS) Tops Q3 EPS by 20c; Reports Cash and Cash Equivalents of $145.1M

Marinus Pharma (NASDAQ: MRNS) reported Q3 EPS of ($0.53), $0.20 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $10.11 million versus the consensus estimate of $2.17 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Goldman "broadly" raises estimates for LTL and truckload stocks